SCHEMBL14982018

SCHEMBL14982018

Cc1ccc(C(=O)N(c2cc(C#CC(C)(C)C)sc2C(=O)O)C2CCN(C)CC2)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NR1I2 O75469 2/20 0.47
▸ CYP2E1 P05181 1/20 0.43
▸ MCHR1 Q99705 2/20 0.36
▸ PDK2 Q15119 2/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ CACNA2D1 P54289 3/20 0.33
▸ OPRM1 P35372 1/20 0.33
▸ HTR2A P28223 2/20 0.33
▸ HTR2C P28335 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ BRD4 O60885 1/20 0.31
▸ TAF1 P21675 1/20 0.31
▸ CECR2 Q9BXF3 1/20 0.31
▸ UBE2M P61081 1/20 0.31
▸ DCUN1D1 Q96GG9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14982007 0.92 NR1I2 (0.47) NR1I2CYP2E1MCHR1PDK2RAB9A
Hydrochloric Acid SCHEMBL1961448 0.91 NR1I2 (0.47) NR1I2CYP2E1MCHR1PDK2RAB9A
SCHEMBL1960213 0.90 NR1I2 (0.43) NR1I2CYP2E1PDK2NPC1RAB9A
SCHEMBL1960212 0.90 NR1I2 (0.43) NR1I2CYP2E1PDK2NPC1RAB9A
SCHEMBL14982017 0.89 CYP2E1 (0.47) NR1I2CYP2E1NPC1RAB9AALDH1A1
SCHEMBL1963185 0.85 NR1I2 (0.45) NR1I2CYP2E1PDK2NPC1RAB9A
SCHEMBL1958434 0.84 NR1I2 (0.47) NR1I2CYP2E1PDK2NPC1RAB9A
SCHEMBL1961686 0.83 NR1I2 (0.39) NR1I2CYP2E1MCHR1PDK2RAB9A
SCHEMBL1961765 0.83 NR1I2 (0.46) NR1I2CYP2E1NPC1RAB9AALDH1A1
SCHEMBL1963188 0.83 NR1I2 (0.46) NR1I2CYP2E1PDK2OPRM1UBE2M

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS HAVCR2, GTF3C3, ZC3HAV1 NR1I2 312/4885CYP2E1 75/4885MCHR1 1503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback